Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 126 results for epilepsies

  1. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

  2. Autism spectrum disorder in under 19s: support and management (CG170)

    This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.

  3. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

  4. Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy?

    effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy? Any explanatory notes(if applicable) For a...

  5. Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets?

    effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance...

  6. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

  7. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  8. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy Interventional procedures guidance

    Question MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy Interventional procedures guidance Any explanatory...

  9. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  10. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

  11. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  12. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  13. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

  14. Further research should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction in concomitant medication and hospital admissions.

    Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction...